FDA Grants Cosmo Pharmaceuticals both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX®)
(WorldNews Netherlands)

Aemcolo Eligible for Additional Market Exclusivity and Priority Review in the United States Drug Candidate Offers Significant Anti-Infective Properties and Unique Delivery Mechanism for Treatment of Travelers` Diarrhea Dublin - October 23, 2017- Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that the U.S. Food and Drug Administration has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for Aemcolo (Rifamycin SV MMX), formerly Zemcolo, for the treatment of patients with travelers` diarrhea. `There have not been any new chemical entities approved to treat colonic infections in years, so resistance to current available drugs is a serious issue. The...